Specifically, ORR was 7.4% in cohort A and 9.9% in cohort B. Median progression-free survival (PFS) was 2.1 months in both cohorts, with a median overall survival (OS) not reached in cohort A and of 17.6 months in cohort B. The expression of PD-L1 was evaluated using a combined positive score (CPS) that is “the fraction of PD-L1 staining cells (both tumor cells, and immune cells) over the total number of viable tumor cells”. This evidence concerns the gene CD274 and neoplasm.